Search

Displaying results 7151 - 7160 of 10000 in total
  1. Drug

    PRX-OTC

    go.drugbank.com/drugs/DB17680
    Experimental

    PRX-OTC is an intracellular enzyme replacement therapy designed to replace missing or defective enzyme in patients with ornithine transcarbamylase deficiency.

  2. Drug

    Terizidone

    go.drugbank.com/drugs/DB12954
    ApprovedInvestigationalWithdrawn

    Terizidone has been used in trials studying the treatment of Tuberculosis, HIV Infections, Multidrug Resistant Tuberculosis, and Extensively-drug Resistant Tuberculosis.

  3. Drug

    Sultamicillin

    go.drugbank.com/drugs/DB12127
    ApprovedWithdrawn

    Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated Pneumonia and Chronic Obstructive Pulmonary Disease (COPD).

    Products: BACTESUL® 375 MG, SULTAMICILINA375 MG
  4. Drug

    Rhizopus arrhizus var. arrhizus

    go.drugbank.com/drugs/DB10441
    Approved

    Rhizopus arrhizus var. arrhizus extract is used in allergenic testing.

  5. Drug

    Puccinia striiformis var. striiformis

    go.drugbank.com/drugs/DB10937
    Approved

    Puccinia striiformis var. striiformis extract is used in allergenic testing.

  6. Drug

    PRX-ASL

    go.drugbank.com/drugs/DB17679
    Experimental

    PRX-ASL is an intracellular enzyme replacement therapy designed to replace the missing or defective enzyme in patients with argininosuccinate lyase deficiency.

  7. Drug

    Endothelin-1

    go.drugbank.com/drugs/DB12652
    Investigational

    Endothelin 1 is under investigation in clinical trial NCT00745693 (The Effects of Diesel Exhaust Inhalation on Vascular Function - the Role of Endothelin).

  8. Drug

    Indisulam

    go.drugbank.com/drugs/DB06370
    Investigational

  9. Drug

    RAF-265

    go.drugbank.com/drugs/DB05984
    Investigational

  10. Drug

    Tasquinimod

    go.drugbank.com/drugs/DB05861
    Investigational

    The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts